Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29058951 | 0.85 | GPBAR1 (0.78) | GPBAR1LMNATDP1MEN1KMT2A | |
| SCHEMBL25754414 | 0.82 | IDH1 (0.53) | GPBAR1LMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL12204335 | 0.82 | LMNA (0.79) | GPBAR1LMNATDP1MEN1KMT2A | |
| SCHEMBL13654932 | 0.78 | GPBAR1 (0.69) | GPBAR1LMNATDP1MEN1KMT2A | |
| SCHEMBL30395319 | 0.78 | GPBAR1 (0.69) | GPBAR1LMNATDP1MEN1KMT2A | |
| SCHEMBL25754376 | 0.77 | IDH1 (0.55) | — | |
| SCHEMBL25754382 | 0.76 | SMN1; SMN2 (0.51) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL25754345 | 0.75 | IDH1 (0.55) | LMNAMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL29058683 | 0.75 | ALDH1A1 (0.82) | GPBAR1LMNATDP1MEN1KMT2A | |
| SCHEMBL30395450 | 0.74 | EPAS1 (1.00) | GPBAR1LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | GPBAR1 1793/4885LMNA 3435/4885TDP1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.